Condition : Rheumatoid Arthritis Interventions : Drug: Sirukumab 100 mg; Drug: Sirukumab 50 mg; Drug: Placebo Sponsor : Janssen Research & Development, LLC Recruiting - verified November 2013

Condition : Rheumatoid Arthritis Interventions : Drug: Sirukumab 100 mg; Drug: Sirukumab 50 mg; Drug: Placebo Sponsors : Janssen Research & Development, LLC; Janssen Research & Development, LLC Recrui...

Condition : Rheumatoid Arthritis Interventions : Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate; Drug: placebo Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Not yet recruiting - verified...

Inclusion Criteria: retrospective:12 months at least first anti-TNF therapy prospective: at maximum 6 months observation AS patients with axial involvment Exclusion Criteria: patients in other AS stud...

Inclusion Criteria: retrospective:12 months at least first anti-TNF therapy prospective: at maximum 6 months observation AS patients with axial involvment Exclusion Criteria: patients in other AS stud...

Condition : Rheumatoid Arthritis Interventions : Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate; Drug: placebo Sponsor : Hoffmann-La Roche Recruiting - verified February 2014

Condition : Rheumatoid Arthritis Interventions : Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate; Drug: placebo Sponsor : Hoffmann-La Roche Recruiting - verified November 2013

Conditions : Back Pain; Coronary Artery Disease; Chronic Obstructive Pulmonary Disease; Diabetes; Hypertension; Multiple Sclerosis; Osteoporosis; Osteoarthritis; Rheumatoid Arthritis; Stroke Intervent...

Inclusion Criteria: retrospective:12 months at least first anti-TNF therapy prospective: at maximum 6 months observation AS patients with axial involvment Exclusion Criteria: patients in other AS stud...

Condition : Rheumatoid Arthritis Interventions : Biological: ABT-122; Biological: Placebo Sponsor : AbbVie Recruiting - verified February 2014